Charla Andrews - Concepedia

Author

Charla Andrews

Also Known As

C A Andrews, C. A. Andrews, C. Andrews, C.A. Andrews, Charla A Andrews, Charla A. Andrews, Charla Andrews, Charla A. Andrews, P. L. Gomez, the VRC 603 Study Team

Publications

10.7K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Institute of Allergy and Infectious Diseases Fred Hutch Cancer Center Armed Forces Research Institute of Medical Science Mahidol Oxford Tropical Medicine Research Unit

About

Charla Andrews is an author at National Institutes of Health specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	24	4.9K
2	Allergy	4	4	2.7K
3	Health Sciences	1	1	26
4	Cell Biology	1	1	393
5	Epidemiology	1	1	56

Charla Andrews

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome Richard A. Koup, Jeffrey T. Safrit, Yaming Cao, Journal of Virology ImmunologyImmunotherapyHuman RetrovirusInitial ControlTemporal Association	1994	2.5K
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Barton F. Haynes, Peter B. Gilbert, M. Juliana McElrath, New England Journal of Medicine	2012	1.8K
Isolation of HTLV-III from Cerebrospinal Fluid and Neural Tissues of Patients with Neurologic Syndromes Related to the Acquired Immunodeficiency Syndrome David D. Ho, T R Rota, Robert T. Schooley, New England Journal of Medicine	1985	1.1K
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines Amy W. Chung, Musie Ghebremichael, Hannah R. Robinson, Science Translational Medicine ImmunologyHuman Phase 2BImmunodominanceImmunotherapyVaccine Target	2014	393
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector Andrew Catanzaro, Richard A. Koup, Mario Roederer, The Journal of Infectious Diseases	2006	313
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, The Lancet	2017	298
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials David C. Montefiori, Chitraporn Karnasuta, Yunda Huang, The Journal of Infectious Diseases	2012	282
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial Julie E. Martin, Mark K. Louder, LaSonji A. Holman, Vaccine VaccinationVaccine DevelopmentMedicineImmunologyTherapeutic Vaccine	2008	271
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection Susan Zolla‐Pazner, Allan C. deCamp, Peter B. Gilbert, PLoS ONE	2014	267
A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial Julie E. Martin, Nancy J. Sullivan, Mary E. Enama, Clinical and Vaccine Immunology	2006	235

Page 1